Analysis of cancer risk in primary immune deficiency (PID) offers insight into the relationship between distinct immune effector functions and cancer. Data on Australian patients (n=1,132) notified voluntarily to the Australasian Society of Clinical Immunology and Allergy PID Registry (1990Registry ( -2008 were linked with national death and cancer registries.
INTRODUCTION
The contribution of immune dysfunction to cancer risk is receiving increasing attention.
Recent findings from population studies in people with HIV and solid organ transplantation have uncovered a quantifiable contribution of immune deficiency to cancer risk. 1 They suggest that predominantly T-cell deficiency is associated with an increased risk of a wide range of cancers, in particular cancers with a known or suspected infectious etiology.
Examinations of immune-related and other risk factors in these cohorts have suggested that impairment of individual immune effector pathways may influence the risk of specific cancers. [2] [3] [4] [5] [6] Studies of the cancer profile and risk determinants in primary immune deficiency (PID) have the potential to provide further insight.
PID comprises more than 150 distinct entities caused by genetic defects that primarily affect specific functional immunity. 7 PID has been associated with a markedly increased risk of cancer, in particular non-Hodgkin lymphoma (NHL). [8] [9] [10] [11] [12] [13] However, the PID cancer risk profile is not well characterized, as the majority of prior studies have been non-populationbased, of small sample size, of limited follow-up and without a matched comparison group.
Other cancers that appear to be associated with specific forms of PID include stomach cancer with common variable immune deficiency (CVID), 8, 11 leukemia with ataxia-telangiectasia (AT), 10, 13 and non-melanocytic skin cancer with cartilage-hair hypoplasia. 12 Here we report the overall and site-specific incidence of cancer relative to the general population for a national cohort of Australians with a diverse range of PID, a majority with predominantly antibody deficiencies.
MATERIALS AND METHODS

Study population
The study included Australian children and adults diagnosed with PID, as notified to 
Data collection
Incident deaths were ascertained using data linkage with the Australian National Death Index. The Index records all deaths in Australian residents, as reported to each of the jurisdictional registers of births, deaths and marriages, since 1980. Incident cancers were ascertained using data linkage with the Australian National Cancer Database, a compilation of data on all incident primary invasive cancers (except non-melanoma skin cancer, C44) The ASCIA Registry is approved to collect data on the first two letters of the first and last name of each patient, as well as the date of birth and sex, enabling probabilistic data linkage. Ethical approval for data linkage was obtained from all relevant institutional ethics committees. The requirement for informed consent from patients was waived because the researchers received only de-identified data.
Statistical analysis
A congenital basis for PID, and therefore immune dysregulation from birth, was assumed for all patients. This assumption extended the person-years (PYs) of follow-up for 16, [20] [21] [22] Cancers were classified according to ICD10, with the exception of Kaposi sarcoma and lymphoid and hematopoietic neoplasms, which were classified according to ICDO3 morphology codes.
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Standardized Incidence Ratios
The ratio of the observed to the expected numbers of cancers, the standardised incidence ratio (SIR), was calculated with exact 95% confidence intervals (CI). The expected numbers of cases were computed based on the general population cancer incidence rates, assuming a Poisson distribution. 24 'All cancer' and site-specific cancer SIRs were calculated for the entire cohort, and separately for men and women, and also for children (less than 16 years of age) and adults.
'All cancer' and site-specific cancer SIRs were also computed for six classifications of PID which grouped individual PID entities with related pathophysiology, 7 as well as for 
Incidence Rate Ratios
To further explore cancer risk with respect to type of PID, a within-cohort analysis was conducted for NHL, the most common cancer in the cohort. Multivariate Poisson regression was used to calculate incidence rate ratios (IRR) with 95% CI for selected PID groupings with adjustment for five-year age group (time-dependent) and sex.
All data analyses were performed using STATA version 10.1 (StataCorp LP, College Station, TX).
RESULTS
The study cohort consisted of 1,132 patients, 53% of whom were male ( Table 1 ). The median age at ASCIA registration was 25 years (range newborn to 95 years) and the mean duration of follow-up was 16 years (SD=5.4 years). A total of 111 (9.8%) deaths were observed during follow-up. Most patients (78%) were classified as having a 'predominantly antibody deficiency' (Table 1) . CVID was the most common entity (n=416), followed by IgG subclass deficiency with or without IgA deficiency (n=215), and there were substantially fewer than 100 patients for most other entities (Supplementary Table 1 ), limiting our ability to make direct comparisons. Table 2 ). There were no cases of Kaposi sarcoma, nor any oral cavity/oropharyngeal, anogenital or brain cancers. No cancers occurred at significantly reduced rates relative to the general population.
Standardised incidence ratios
'All cancer' and site-specific SIRs were similar for men and women, with the exception of thymoma, which occurred in males only ( Table 3 ). The SIRs for 'all cancer' and NHL were significantly increased in both children and adults (Table 4) .
Major PID classifications
SIRs for 'all cancer' and for NHL were significantly increased for patients with 'predominantly antibody deficiencies' and 'other well-defined immunodeficiency syndromes' (Table 5 ). The SIR for leukemia was significantly increased for patients with 'diseases of immune dysregulation'. No other site-specific SIRs were significantly increased for other PID classifications.
Individual PID conditions
SIRs for 'all cancer' were significantly increased in patients with CVID (n=416) and AT (n=10) ( Table 6 ). In patients with CVID, SIRs were also significantly increased for NHL, and cancers of the breast (females) and thymus. Both thymus gland cancers were diagnosed in males (aged 48 and 53 years), and both were thymomas. The SIR for stomach cancer was elevated on the basis of two cases; a diffuse adenocarcinoma in a 65 year old and a carcinoma of unspecified morphology in a 56 year old. In patients with AT, the SIR for NHL was significantly increased, based on a single case. 
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In patients with IgG subclass deficiency (n=244), the SIR for leukemia was significantly increased on the basis of two cases. There were no cancers diagnosed in patients with selective IgA deficiency. In patients with X-linked agammaglobulinemia (n=62), the SIR for stomach cancer was significantly increased based on a single case of diffuse adenocarcinoma in a 45 year old.
Incidence rate ratios
Risk of NHL was significantly associated with some PID subtypes after adjustment for age and sex. Compared with predominantly antibody deficiencies excluding CVID, CVID was associated with a five-fold increased risk (IRR 5.75, 95% CI 1.25-26.5), 'other welldefined immunodeficiency syndromes' was associated with a nine-fold increased risk (IRR 9.23, 95% CI 1.23-69.0), and all other PID subtypes combined showed no excess risk (IRR 1.52, 95% CI 0.14-16.8).
DISCUSSION
This national, population-based cohort study identified a modest excess risk of any cancer, and a strong excess risk of a small number of cancers (NHL, stomach, thymus, and leukemia) in patients with PID relative to the general population. Within the statistical power afforded by the study, the data suggest two novel insights. First, PID characterized predominantly by antibody deficiency may be associated with a narrower range of solid cancers than predominantly T-cell deficiency after solid organ transplantation or in HIV infection.
1 Second, the excess cancer risk may be confined to certain forms of immunodeficiency within PID, and further, to specific disease entities within those broad phenotypes. This study demonstrates the future potential of PID, with its increasingly well characterized genetic basis and forms of immune deficiency and increasing life expectancy, to contribute to our understanding of the role of immune function in cancer control. are also believed to play a role in lymphomagenesis. Our within-cohort analysis suggests that the form of functional immune impairment in CVID and 'other well-defined immunodeficiency syndromes' is associated with a significantly greater risk of NHL relative to all other predominantly antibody deficiencies combined.
Our risk estimate for stomach cancer for all PID (SIR 6.10) is similar to the only prior population-based estimate for CVID and IgA deficiency combined (SIR 7.5; n=562), and is appreciably lower than a hospital-based estimate for CVID (47-fold). 8 The follow-up of those with premalignant gastric lesions. 37 We observed a large excess risk for thymoma on the basis of two cases occurring in patients with CVID. Goods syndrome, or 'thymoma with immunodeficiency', is a rare form of predominantly antibody deficiency characterized by the occurrence of adult-onset hypogammaglobulinemia either before or after the diagnosis of thymoma. 38 Although regarded by some as a subset of CVID, it is now classified as a separate entity.
We found a significantly increased risk of leukemia for all PID, 'diseases of immune dysregulation', and 'IgG subclass deficiency'. Despite the strong prior evidence, we did not observe an excess risk of leukemia in AT. 10, 13 Our observation of an increased relative risk of breast cancer in CVID is novel, apart from recent case reports in two young women.
explanation. This finding is worthy of further investigation as mothers of children with AT appear to be at increased risk 10 and no excess risk is observed in acquired and iatrogenic immunodeficiency.
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The evidence accumulated to-date suggests that the cancer profile in PID may differ from that observed in iatrogenic and acquired immunodeficiency, where a wide range of solid cancers with an infectious aetiology occur at excess risk. 1 Of the many solid cancers with an established infectious cause, 40 only stomach cancer appears to occur at a significantly higher rate in PID. [8] [9] [10] [11] [12] [13] The size of our cohort, and the comparative rarity of infection-related cancers such as Kaposi sarcoma and anogenital and orpharyngeal cancers cannot be ruled out, but there are also other possible explanations. First, the cancer profile may reflect a lower rate of infection by the causally associated sexually acquired infectious agents 40 in this patient group. Second, in comparison to HIV-related and iatrogenic immunosuppression, primary antibody deficiency disorders may occur in the context of relatively preserved T-cell effector function, and T-cell dysfunction may carry the majority of the attributable risk. For example, in HIV, Kaposi Sarcoma risk is strongly inversely associated with CD4+ T-cell count. 41, 42 In CVID, however, only a small subset (<10%) of patients appear to have very low CD4 counts. 43 A final possibility is that immunoglobulin replacement therapy, used in 71% of the cohort, 15 is associated with a reduced risk of cancer in PID. If true, such an effect would be consistent with the reduction in risk of some cancers after HAART use in HIV, 17 and after the removal of iatrogenic immunosuppression in kidney transplant recipients. 44 It also accords with a case report of regression of Kaposi sarcoma in a HIV patient after IVIG therapy.
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This study utilized one of the world's largest national PID registers and national death and cancer notifications to enable unbiased death and cancer ascertainment relative to the general population. Furthermore, it is the first study to examine site-specific cancer risk across the spectrum of PID subtypes, allowing comparisons between some PID conditions registration of an estimated 34-37% of its target population, 15 and potentially misclassification error, due to misdiagnosis. 7 In particular, it is possible that patients originally diagnosed with CVID may be subsequently diagnosed with XLP disease or CD40L deficiency, rare conditions known to be associated with cancer.
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In addition, our analyses were based on the assumption that immune dysfunction was present for up to 15 years prior to ASCIA registration. Even though our approach accords with the congenital basis of these conditions, it would over-estimate the person-years at risk for cancer if adult-onset disorders arose by somatic genetic error later in life. Nevertheless, our approach does offset the diagnostic delay typically experienced for PID, particularly for conditions such as CVID that are usually diagnosed in adulthood. 47 On the other hand, although survival adjustment was performed to account for the retrospective period of followup, survival bias may not have been completely eliminated, which would also over-estimate the person-years at risk of cancer and weaken the PID-cancer association. Despite these limitations, our risk estimates for CVID and IgA deficiency are of similar magnitude to those obtained for a smaller cohort based on well-defined diagnostic criteria and with prospective follow-up for cancer.
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Although there is long-standing evidence of a strong link between PID and cancer, the association has been understudied. As the life expectancy of people with PID increases due to improvements in the surveillance, prevention and treatment of chronic infections, the For All malignant neoplasms C00-C96, excluding C44 58 36.2 1.60 (1.22-2.07) Abbreviations: O observed number of cases; E expected number of cases; SIR standardised incidence ratio; CI confidence interval. *one-tail, 97.5% CI instead of 95% CI because of zero observation †Lymphoid and hematopoietic neoplasms were classified according to current guidelines 23 and include 2 cases with ICDO3 9960 morphology and ICD10 D47 topography ‡ Diffuse large B-cell lymphoma (n=1), follicular lymphoma (n=3), Burkitt lymphoma/leukemia (n=1), small lymphocytic lymphoma (n=1), extranodal marginal zone lymphoma (MALT) type (n=1; body site location not specified in national cancer registry records), peripheral T-cell lymphoma (n=1) unclassified, cutaneous T-cell lymphoma unclassified (n=1), Waldenström macroglobulinaemia (n=1), NHL unclassified (n=6) §Chronic myeloproliferative leukemia (n=2), acute myeloid leukemia (n=1), and myeloid neoplasms unclassified (n=1) *C00-C96, excluding C44 †one-tail, 97.5% CI instead of 95% CI because of zero observation. ‡ Diffuse large B-cell lymphoma (n=1), follicular lymphoma (n=2), Burkitt lymphoma/leukemia (n=1), small lymphocytic lymphoma (n=1), extranodal marginal zone lymphoma (MALT) type (n=1), peripheral T-cell lymphoma (n=1) unclassified, cutaneous Tcell lymphoma unclassified (n=1), Waldenström macroglobulinaemia (n=1), and NHL unclassified (n=4) §Diffuse large B-cell lymphoma (n=1) ║ Follicular lymphoma (n=1), NHL unclassified (n=1) *C00-C96, excluding C44 †one-tail, 97.5% CI instead of 95% CI because of zero observation. ‡ Diffuse large B-cell lymphoma (n=1), follicular lymphoma (n=2), Burkitt lymphoma/leukemia (n=1), small lymphocytic lymphoma (n=1), extranodal marginal zone lymphoma (MALT) type (n=1), peripheral T-cell lymphoma (n=1) unclassified, Waldenström macroglobulinaemia (n=1), and NHL unclassified (n=3) §NHL unclassified (n=1)
